💊 Public Health ← Back to All Articles
Six days ago, on International Overdose Awareness Day, the CDC quietly launched something it has never had before: a single, centralized dashboard tracking every fatal and nonfatal overdose in the country in close to real time. The timing wasn’t an accident. The numbers behind it tell a story that’s more complicated than “overdose deaths are falling” — because the drug supply killing Americans has changed faster than the headlines have caught up.
The Headline Number
The latest monthly provisional data from the CDC’s National Vital Statistics System predicts 67,798 drug overdose deaths in the 12 months ending March 2026 — a 12.3% decline from the same period a year earlier. It’s the continuation of a trend that began after fatalities peaked above 110,000 a year in 2023. By any measure, that is real progress, and it deserves to be reported as such. See the CDC’s provisional overdose data for the full series.
Why CDC Built a New Data Channel
On August 31, the agency launched the Overdose Prevention Data Channel, pulling together three separate surveillance systems — SUDORS, the DOSE system, and NVSS — into one public-facing tool. “The continued decline in predicted overdose deaths is encouraging, but progress is not a finish line,” said Grant Baldwin, director of CDC’s Division of Overdose Prevention, in the release announcing the launch. The subtext is hard to miss: the agency that just posted a good-news number about the opioid crisis felt it needed a bigger, faster instrument to watch what comes next.
The Drug the Antidote Can’t Touch
What comes next is xylazine. Sold on the street as “tranq,” it’s a veterinary sedative that dealers increasingly mix into fentanyl to extend its effects — and because it isn’t an opioid, naloxone, the drug that reverses opioid overdoses and has been central to the recent decline in deaths, does nothing to stop it. The DEA has now found fentanyl-xylazine mixtures in 48 of 50 states, and as of the most recent seizure data, xylazine turned up in roughly 30% of fentanyl powder tested nationally, according to the DEA’s threat assessment. Beyond the overdose risk, users injecting xylazine-laced drugs frequently develop severe, necrotic wounds that can lead to amputation — a public health consequence that doesn’t show up in a mortality count at all.
A Bipartisan Response, Still Stalled
The policy world has noticed. A coalition of 41 state attorneys general — spanning both parties — is now pushing Congress to pass the Combating Illicit Xylazine Act, which would classify xylazine as a Schedule III controlled substance and restrict its diversion from legitimate veterinary supply chains. It’s one of the rarer issues in Washington with near-unanimous state-level support. It has not yet become federal law.
The tool that cut overdose deaths by double digits doesn’t work on the drug that’s replacing what it was built to stop.
What This Means for the Index
A falling overdose count is genuinely good news, and it’s worth saying plainly: fewer Americans are dying than were dying two years ago. But the Index isn’t just tracking a body count — it’s tracking whether the systems meant to protect people can keep pace with how fast harm mutates. Naloxone became a national success story because it was simple, effective, and widely distributed. Xylazine is a reminder that the drug supply doesn’t hold still to let a solution work indefinitely, and that the gap between “the numbers are improving” and “the underlying problem is solved” is exactly where policy tends to stall out — bipartisan bills included.
Sunday September 6th 2026
— David, The Moral Decay Index